Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Oral Synbiotics and L-carnitine on Lipid Profiles and Liver Function in NAFLD
IRCT20230212057393N1Phase 3Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of levocarnitine in metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by Mazandaran University of Medical Sciences. Primary endpoints: Change in lipid profile and Change in liver function tests. Started Apr 2023; status: completed.
02
Drugs
levocarnitine
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT20230212057393N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230212057393N1.